Artelo Biosciences, Inc. (ARTL) Misses Q2 EPS by 548c

Artelo Biosciences, Inc. (NASDAQ: ARTL) reported Q2 EPS of ($5.61), $5.48 worse than the analyst estimate of ($0.13).

For earnings history and earnings-related data on Artelo Biosciences, Inc. (ARTL) click here.

You May Also Be Interested In

• LeonaBio (LONA) Price Target Cut to $17 by Citizens Amid Pipeline Development
• Edge Total Intelligence Provides Business Update: Preliminary Second Quarter and First-Half Revenue, Special AGM Matters, and Strategic Growth
• Deutsche Bank Upgrades PennyMac Mortgage Investment Trust (PMT) to Buy